Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Several possible studies

Story checked

Immunotherapy combination extends survival in advanced endometrial cancer (opens in a new tab)

medicalxpress.com · 2026-10-26

Short answerEvidenceSource

Short answer

Several possible studies

Study not confirmed.

Several potential source studies were identified, but no single match could be confirmed. The article's claims remain unverified.

16 candidate papersExplore the search results

These papers were considered as possible sources, but none could be confirmed as the study behind this story.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Multiple potential source studies identified.

Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.

View article claims
3

Search result

Several studies could fit.

Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.

The literature search

16 candidate papers

Studies identified during the search

These papers appeared in the search for the story’s source. None was confirmed as a direct match. Inclusion here does not mean a paper supports or contradicts the story, or that its full text was reviewed.

Show 12 more search results
Then inspect each claim

Evidence layer

Claim by claim

The article's claims are listed below. Without a confirmed source study, they have not been assessed as supported or unsupported.

Claim 1 of 6Not checkedAn immunotherapy-based regimen combining durvalumab and the PARP inhibitor olaparib demonstrated encouraging long-term survival outcomes for patients with advanced or recurrent endometrial cancer, according to new trial results presented by researchers from The University of Texas MD Anderson Cancer Center.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 2 of 6Not checkedIn the global phase 3 DUO-E trial, treatment with durvalumab plus chemotherapy followed by durvalumab and olaparib achieved a median overall survival of 51.1 months, which was 11.5 months longer than with chemotherapy alone.View evidenceHide evidence

As statedmedian overall survival 51.1 months; 11.5 months longer

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 3 of 6Not checkedThe study previously met its primary progression-free survival end points, and the current analysis evaluated overall survival and long-term safety profiles; no new safety concerns were observed and side effects remained consistent with previous findings.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 4 of 6Not checkedResearchers also reported durable benefits across secondary end points, including longer time before subsequent therapy and longer time on treatment, with 36-month survival of 63.4% in the durvalumab-plus-olaparib arm versus 52% in the chemotherapy arm.View evidenceHide evidence

As stated63.4% vs 52% at 36 months

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 5 of 6Not checkedThe article says additional benefits were observed among patients with mismatch repair–proficient (pMMR) tumors, and that adding olaparib may help explain the broader benefit across subgroups.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 6 of 6Not checkedThe trial randomized 718 patients with advanced or recurrent endometrial cancer to one of three regimens, and researchers will continue the DUO-E study for a final overall survival analysis.View evidenceHide evidence

As stated718 patients

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Finally, the search trail

Method layer

Study not confirmed.

The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.

Search results

Candidate papers, not confirmed sources.

PubMed, Crossref, Europe PMC · 15 candidate papers

Explore all search results